Press releases
OCT Announces Exclusive Joint Development Agreement With Ex-Google AI Experts, Hypatia AI to Develop an AI-Enabled Asset to Scale Its Drug Discovery Pipeline
Oxford Cannabinoid Technologies (“OCT” or “the Company”) is pleased to announce the successful completion of ‘proof of concept’ of its AI-enabled drug discovery asset, which it is developing in collaboration with New York-based tech consultancy, Hypatia AI (“Hypatia”).
